title: KEYTRUDA速 (pembrolizumab) Plus Padcev速 (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
source: Yahoo
date: 2025-10-18
url: https://finnhub.io/api/news?id=0017d9660b12eb9471e62bc58c100d5030161b97890c186d5dd3c7bec516d063
RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA速 (pembrolizumab) plus Padcev速 (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f
